Evidence map›Paper›PMID 25071369›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2014

A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.

David M Kern, Setareh A Williams, Ozgur Tunceli, Catrin Wessman, Siting Zhou, Ned Pethick, Hanaa Elhefni, Frank Trudo

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

David M KernHealthCore Inc., Wilmington, DE, US.
Setareh A WilliamsAstraZeneca, Wilmington, DE, USA.
Ozgur TunceliHealthCore Inc., Wilmington, DE, US.
Catrin WessmanAstraZeneca, Mölndal, Sweden.
Siting ZhouHealthCore Inc., Wilmington, DE, US.
Ned PethickAstraZeneca, Wilmington, DE, USA.
Hanaa ElhefniAstraZeneca, Wilmington, DE, USA.
Frank TrudoAstraZeneca, Wilmington, DE, USA.
AstraZeneca (United States) · USWilmington University · USAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare clinical and demographic characteristics, resource utilization and costs of chronic obstructive pulmonary disease (COPD) patients prior to initiating budesonide-formoterol combination (BFC) or tiotropium-maintenance therapy. MATERIALS AND

methodsThis cross-sectional study used claims-based diagnosis to identify COPD patients in the HealthCore Integrated Research Database who initiated BFC or tiotropium therapy between March 1, 2009 and January 31, 2012 (intake period); the index date was defined as the initial prescription fill for either agent. Patients diagnosed with respiratory tract cancer or receiving inhaled corticosteroids/long-acting β2-adrenergic agonists or tiotropium in 12 months prior to index date were excluded. Categorical variables were evaluated with χ(2) tests; mean cost differences were evaluated using γ-regression.

resultsOverall, 6,940 BFC and 10,831 tiotropium patients were identified. The BFC group was younger (mean age 64 versus 67 years), with a greater proportion of females (54% versus 51%). BFC-treated patients had more comorbid respiratory conditions, including asthma (25% versus 13%), but fewer comorbid cardiovascular conditions, including atherosclerosis (7% versus 10%) and myocardial infarction (4% versus 6%). A greater proportion of BFC patients received prior respiratory medication, including oral corticosteroids (46% versus 35%) and short-acting β2-agonists (44% versus 35%). Tiotropium-treated patients had a greater mean number of COPD-related outpatient visits (4.6 versus 4.1). BFC-treated patients had lower total all-cause ($17,259 versus $17,926) and COPD-related ($1,718 versus $1,930) health care costs, driven by lower all-cause and COPD-related inpatient expenditures.

conclusionInitiators of BFC or tiotropium showed differences in clinical and demographic characteristics and health care utilization and costs prior to starting COPD maintenance therapy.

Indexed as

Databases, FactualAdrenergic beta-2 Receptor AgonistsAdultAgedAge FactorsBronchodilator AgentsBudesonideChi-Square DistributionCholinergic AntagonistsComorbidityCross-Sectional StudiesData MiningDrug CombinationsDrug CostsEthanolaminesFemaleAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsBudesonideCholinergic AntagonistsDrug CombinationsEthanolaminesFormoterol FumarateGlucocorticoidsScopolamine DerivativesTiotropium Bromidechronic respiratory conditionhealth care utilization and costsobservational studyoutcome researchretrospective analysis

Identifiers

PMID25071369
PMCPMC4111649
OpenAlexW2024273831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.